Skip to main content

Global Newsroom

CSL Behring Patient Zahra Khan, living with hereditary angioedema

Global Newsroom

Recent News Releases

Featuring releases from CSL, CSL Behring, CSL Seqirus and CSL Vifor.

May 20, 2024

Data follow the approval of the world's first self-amplifying (sa-mRNA) COVID-19 vaccine for adults in Japan. These results add to recently published data on ARCT-154 demonstrating superior...

Read more news from CSL

Recent News Releases
Jan 16, 2024

Findings show that convenience of treatment and flexibility of administration, such as at-home treatment options, are of high importance to patients KING OF PRUSSIA, Pa., Jan. 16, 2024...

Read more news from CSL Behring

Recent News Releases
Jun 11, 2024

CSL Seqirus to provide 665,000 pre-pandemic (zoonotic) vaccines to support fifteen EU and EEA Member States. Outbreaks of highly pathogenic avian influenza (HPAI) viruses in birds and poultry have...

Read more news from CSL Seqirus

Recent News Releases
Apr 24, 2024

First non-immunosuppressive therapy for the treatment of IgA Nephropathy (IgAN) approved in Europe Conditional marketing authorization is based on statistically significant and clinically...

Read more news from CSL Vifor

Read all company news releases

Media Resources

Media Contacts

Victoria, Australia
Phone: +61 450 909 211

CSL Behring
North America


Asia Pacific

CSL Seqirus
UK, EMA, Argentina
Olga Scott
Phone: +44 (0) 777 167 3910

North America
Tiffany Cody
Phone: +1 908 370 1863

Asia Pacific
Hamish Walsh
Phone: 0422 424 338

Global Commercial Development
Emmanuella Dekonor
Phone: +44 7920500496

CSL Plasma
United States

Follow Us Online
  • linkedin icon
  • twitter icon
  • youtube icon
  • facebook icon
  • instagram icon
Get our latest news releases in your inbox
* Required Fields